The Guillain-Barre Syndrome drugs in development market research report provides comprehensive information on the therapeutics under development for Guillain-Barre Syndrome, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Guillain-Barre Syndrome. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Guillain-Barre Syndrome and features dormant and discontinued products.
GlobalData tracks 14 drugs in development for Guillain-Barre Syndrome by 13 companies/universities/institutes. The top development phase for Guillain-Barre Syndrome is preclinical with seven drugs in that stage. The Guillain-Barre Syndrome pipeline has 12 drugs in development by companies and two by universities/ institutes. Some of the companies in the Guillain-Barre Syndrome pipeline products market are: Cresence, Nervosave Therapeutics and Augusta University.
The key targets in the Guillain-Barre Syndrome pipeline products market include Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5), Complement C1q Subcomponent, and Complement Component C6 (C6).
The key mechanisms of action in the Guillain-Barre Syndrome pipeline product include Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) Inhibitor with two drugs in Preclinical. The Guillain-Barre Syndrome pipeline products include seven routes of administration with the top ROA being Intravenous and eight key molecule types in the Guillain-Barre Syndrome pipeline products market including Monoclonal Antibody, and Small Molecule.
Guillain-Barre Syndrome overview
Guillain-Barre syndrome (GBS) is a disorder in which the body’s immune system attacks part of the peripheral nervous system. The first symptoms of this disorder include varying degrees of weakness or tingling sensations in the legs. In many instances the symmetrical weakness and abnormal sensations spread to the arms and upper body. These symptoms can increase in intensity until certain muscles cannot be used at all and, when severe, the person is almost totally paralyzed. Risk factors include influenza virus, mycoplasma pneumonia, Hodgkin’s lymphoma, and Epstein-Barr virus.
For a complete picture of Guillain-Barre Syndrome’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
